General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 4.150
0.00 (0.00%)
Mar 12, 2026, 2:59 PM CST
General Biologicals Revenue
In the year 2025, General Biologicals had annual revenue of 215.74M TWD, down -14.36%. General Biologicals had revenue of 110.73M in the half year ending June 30, 2025, a decrease of -17.18%.
Revenue
215.74M
Revenue Growth
-14.36%
P/S Ratio
1.17
Revenue / Employee
2.66M
Employees
81
Market Cap
252.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 215.74M | -36.19M | -14.36% |
| Dec 31, 2024 | 251.93M | -12.90M | -4.87% |
| Dec 31, 2023 | 264.83M | -105.63M | -28.51% |
| Dec 31, 2022 | 370.46M | -181.20M | -32.85% |
| Dec 31, 2021 | 551.66M | 75.79M | 15.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Prince Pharmaceutical | 1.06B |
| Excelsior Biopharma | 906.42M |
| Anxo Pharmaceutical | 843.26M |
| DV Biomed | 794.18M |
| Winston Medical Supply | 700.07M |
| GeneFerm Biotechnology | 663.87M |
| Mediera | 233.15M |
| Bioray Biotech | 222.73M |